Evidence map›Paper›PMID 28341842›Full record

ArticleScientific reports2017

A scoring system to predict breast cancer mortality at 5 and 10 years.

Esther Paredes-Aracil, Antonio Palazón-Bru, David Manuel Folgado-de la Rosa, José Ramón Ots-Gutiérrez, Antonio Fernando Compañ-Rosique, Vicente Francisco Gil-Guillén

Abstract read
In one paragraph

Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Observational
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Esther Paredes-AracilSurgery Service, General University Hospital of Elda, Elda, Alicante, Spain.
Antonio Palazón-BruDepartment of Clinical Medicine, Miguel Hernández University, San Juan de Alicante, Alicante, Spain. apalazon@umh.es.
David Manuel Folgado-de la RosaDepartment of Clinical Medicine, Miguel Hernández University, San Juan de Alicante, Alicante, Spain.
José Ramón Ots-GutiérrezSurgery Service, Marina Baixa Hospital, La Vila Joiosa, Alicante, Spain.
Antonio Fernando Compañ-RosiqueDepartment of Pathology and Surgery, Miguel Hernández University, San Juan de Alicante, Alicante, Spain.
Vicente Francisco Gil-GuillénDepartment of Clinical Medicine, Miguel Hernández University, San Juan de Alicante, Alicante, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Although predictive models exist for mortality in breast cancer (BC) (generally all cause-mortality), they are not applicable to all patients and their statistical methodology is not the most powerful to develop a predictive model. Consequently, we developed a predictive model specific for BC mortality at 5 and 10 years resolving the above issues. This cohort study included 287 patients diagnosed with BC in a Spanish region in 2003-2016. MAIN OUTCOME VARIABLE: time-to-BC death. Secondary variables: age, personal history of breast surgery, personal history of any cancer/BC, premenopause, postmenopause, grade, estrogen receptor, progesterone receptor, c-erbB2, TNM stage, multicentricity/multifocality, diagnosis and treatment. A points system was constructed to predict BC mortality at 5 and 10 years. The model was internally validated by bootstrapping. The points system was integrated into a mobile application for Android. Mean follow-up was 8.6 ± 3.5 years and 55 patients died of BC. The points system included age, personal history of BC, grade, TNM stage and multicentricity. Validation was satisfactory, in both discrimination and calibration. In conclusion, we constructed and internally validated a scoring system for predicting BC mortality at 5 and 10 years. External validation studies are needed for its use in other geographical areas.

Indexed as

AgedBreast NeoplasmsCohort StudiesFemaleHumansNeoplasm StagingRisk Factors

Identifiers

PMID28341842
PMCPMC5428660

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.